

Open Peer Review on Qeios

## Brilanestrant

National Cancer Institute

## Source

National Cancer Institute. <u>Brilanestrant</u>. NCI Thesaurus. Code C106235.

An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.

Qeios ID: LFI53R · https://doi.org/10.32388/LFI53R